Drugs prevent heart damage during breast cancer treatment, study show

November 29, 2016
Ian Paterson checks up on study participant Debbie Cameron. Credit: University of Alberta

Heart medication taken in combination with chemotherapy reduces the risk of serious cardiovascular damage in patients with early-stage breast cancer, according to results from a new landmark clinical trial.

Existing research has shown some cancer therapies such as Herceptin greatly improve survival rates for early-stage breast cancer, but come with a fivefold risk of heart failure—a devastating condition as life-threatening as the cancer itself.

A new five-year study, led by researchers at the University of Alberta and Alberta Health Services and funded by the Canadian Institutes of Health Research (CIHR) and Alberta Cancer Foundation, shows that two kinds of heart medications, and ACE inhibitors, effectively prevent a drop in heart function from cancer treatment.

"We think this is practice-changing," said Edith Pituskin, co-investigator of the MANTICORE trial. "This will improve the safety of the that we provide."

Pituskin, an assistant professor in the Faculty of Nursing and Faculty of Medicine & Dentistry at the U of A, published their findings Nov. 28 in the Journal of Clinical Oncology.

In the double-blind trial, 100 patients from Alberta and Manitoba with were selected at random to receive either a beta blocker, ACE inhibitor or placebo for one year. Beta blockers and ACE inhibitors are drugs used to treat several conditions, including heart failure.

Cardiac MRI images taken over a two-year period showed that patients who received the beta blockers showed fewer signs of heart weakening than the placebo group. The ACE inhibitor drug also had heart protection effects.

Study lead Ian Paterson, a cardiologist at the Mazankowski Alberta Heart Institute and associate professor with the U of A's Department of Medicine, said these medications not only safeguard against damage to the heart, but may improve breast cancer survival rates by limiting interruptions to chemotherapy treatment. Any time a patient shows signs of heart weakening, he said, chemotherapy is stopped immediately, sometimes for a month or two months until returns to normal.

"We are aiming for two outcomes for these patients—we're hoping to prevent heart failure and we're hoping for them to receive all the chemotherapy that they are meant to get, when they are supposed to get it—to improve their odds of remission and survival."

Family history a concern for patient

Patients with often experience fatigue, shortness of breath or even death, making it "an equally devastating disease with worse prognosis than breast cancer," Paterson said.

Brenda Skanes has a history of cardiovascular problems in her family—her mom died of a stroke and her dad had a heart attack. She was eager to join the trial, both for her own health and the health of other .

"I met survivors through my journey who experienced heart complications caused by Herceptin. If they had access to this, maybe they wouldn't have those conditions now," she said. "Me participating, it's for the other survivors who are just going into treatment."

With two daughters of her own and a mother who lost her fight with colon cancer, study participant Debbie Cameron says she'd do anything to ensure prevent others from going through similar upheaval.

"My daughters are always in the back of my mind and the what ifs—if they're diagnosed, what would make their treatment safer, better," Cameron said. "Anything I could do to make this easier for anybody else or give some insight to treatment down the road was, to me, a very easy decision."

Pituskin said the study team, which also includes collaborators from the AHS Clinical Trials Unit at the Cross Cancer Institute and the University of Manitoba, represents a strong mix of research disciplines, particularly the oncology and cardiology groups. She said the results would not have been possible without funding support from CIHR and the Alberta Cancer Foundation.

"Local people in Alberta supported a study that not only Albertans benefited from, but will change, again, the way care is delivered around the world."

The results are expected to have a direct impact on clinical practice guidelines in Canada and beyond.

"Every day in Canada, around 68 women are diagnosed with . This discovery holds real promise for improving these women's quality of life and health outcomes," said Stephen Robbins, scientific director of CIHR's Cancer Research Institute.

"We couldn't be more pleased with this return on our investment," said Myka Osinchuk, CEO of the Alberta Cancer Foundation. "This clinical research will improve treatment and make life better not only for Albertans facing cancer, but also for those around the world."

Paterson said the research team is also investigating how to prevent in patients with other cancers, noting several other therapies have been linked to complications.

Explore further: Drugs prevent heart damage during breast cancer treatment, study shows

Related Stories

Drugs prevent heart damage during breast cancer treatment, study shows

December 9, 2015
Heart medication taken in combination with chemotherapy reduces the risk of serious cardiovascular damage in patients with early-stage breast cancer, according to results from a new landmark clinical trial.

U of A researchers hope to stop heart disease

June 2, 2011
Researchers in the Faculty of Medicine & Dentistry are trying to reverse a devastating trend: cancer survivors developing cardiovascular disease, one of the top two killers in Canada.

Many breast cancer patients don't get treatment for heart problems

June 3, 2014
Only a third of older breast cancer patients saw a cardiologist within 90 days of developing heart problems, in a study presented at the American Heart Association's Quality of Care and Outcomes Research 2014 Scientific Sessions.

Breast cancer awareness: What women need to know

September 28, 2016
As national Breast Cancer Awareness Months begins next week, breast health expert Dr. Sharon Koehler of New York Institute of Technology College of Osteopathic Medicine, says women need to know the following five things:

Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any age

April 19, 2016
Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute ...

ESC launches novel paper on tackling cardiac toxicity of anticancer therapies

August 27, 2016
The European Society of Cardiology has launched a novel position paper, under the auspices of its Committee for Practice Guidelines, on tackling the cardiac toxicity of anticancer therapies. The cardio-oncology paper is published ...

Recommended for you

Researchers discover specific tumor environment that triggers cells to metastasize

November 21, 2017
A team of bioengineers and bioinformaticians at the University of California San Diego have discovered how the environment surrounding a tumor can trigger metastatic behavior in cancer cells. Specifically, when tumor cells ...

New study points the way to therapy for rare cancer that targets the young

November 21, 2017
After years of rigorous research, a team of scientists has identified the genetic engine that drives a rare form of liver cancer. The findings offer prime targets for drugs to treat the usually lethal disease, fibrolamellar ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.